Skip to main content

Advertisement

Log in

Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

The study was designed to create a primary cell culture of uveal melanoma and to evaluate its resistance to chemotherapy. Of the obtained 20 samples of uveal melanoma, the primary cultures with proliferation sufficient for MTT test were derived in only 7 cases. However, even these cultures were unable to survive more than 4 passages; the cells accumulated melanin and underwent apoptosis. Retinol palmitate and nepafenac produced no cytotoxic effect on uveal melanoma cells. Of 5 cultures treated with sodium valproate (Convulex), no pronounced cytotoxic effect was observed in one culture (UM4); in 2 cultures, 50% cells died in the presence of the lowest drug concentration of 1.88 mg/ml; and in 2 cultures, the same effect was achieved at drug concentrations 7-10 mg/ml. The cytotoxic effect of treosulfan was evaluated in only 4 cultures of uveal melanoma: the drug exhibited pronounced antitumor activity on all cultures, in 2 cases, it was effective at a concentration of 0.16 mg/ml. Gemcitabine in a concentration of 2.5 mg/ml produced a pronounced cytotoxic effect in 4 out of 7 cultures (death of 70-80% cells) and induced death of ~45% cells in the remaining 3 cultures. Mitoxantrone had ambiguous effect: in 2 of 5 cultures, the drug in high concentrations stimulated the growth of tumor cells, but in 3 cultures, the drug even in minimum concentrations induced death of 70-80% cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Grishina EE, Lerner MYu, Gemdzhian EG. Epidemiology of uveal melanomas in Moscow. Al’manakh Klin. Med. 2017;45(4):321-325. Russian.

    Article  Google Scholar 

  2. Saakyan SV, Amiryan AG, Tsygankov AYu, Loginov VI, Burdennyy AM. Mutations in oncogenes GNAQ and GNA11 in uveal melanoma patients. Mol. Med. 2014;(2):34-37. Russian.

    Article  Google Scholar 

  3. Álvarez-Rodríguez B, Latorre A, Posch C, Somoza Á. Recent advances in uveal melanoma treatment. Med. Res. Rev. 2017;37(6):1350-1372.

    Article  Google Scholar 

  4. Angi M, Versluis M, Kalirai H. Culturing uveal melanoma cells. Ocul. Oncol. Pathol. 2015;1(3):126-132.

    Article  Google Scholar 

  5. Atzpodien J, Terfloth K, Fluck M, Reitz M. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother. Pharmacol. 2008;62(4):685-688.

    Article  CAS  Google Scholar 

  6. Becker JC, Kämpgen E, Bröcker E. Classical chemotherapy for metastatic melanoma. Clin. Exp. Dermatol. 2000;25(6):503-508.

    Article  CAS  Google Scholar 

  7. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS). COMS report No. 15. Arch. Ophthalmol. 2001;119(5):670-676.

  8. Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin. Cancer Res. 2012;18(2):408-416.

    Article  CAS  Google Scholar 

  9. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J. Clin. Oncol. 1997;15(7):2589-2595.

    Article  CAS  Google Scholar 

  10. Marshall JC, Fernandes BF, Di Cesare S, Maloney SC, Logan PT, Antecka E, Burnier MN Jr. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007;28(9):2053-2058.

    Article  CAS  Google Scholar 

  11. McNamara M, Clynes M, Dunne B, NicAmhlaoibh R, Lee WR, Barnes C, Kennedy SM. Multidrug resistance in ocular melanoma. Br. J. Ophthalmol. 1996;80(11):1009-1012.

    Article  CAS  Google Scholar 

  12. Moschos MM, Dettoraki M, Androudi S, Kalogeropoulos D, Lavaris A, Garmpis N, Damaskos C, Garmpi A, Tsatsos M. The role of histone deacetylase inhibitors in uveal melanoma: current evidence. Anticancer Res. 2018;38(7):3817-3824.

    Article  CAS  Google Scholar 

  13. Nayman T, Bostan C, Logan P, Burnier MN Jr. Uveal melanoma risk factors: a systematic review of meta-analyses. Curr. Eye Res. 2017;42(8):1085-1093.

    Article  Google Scholar 

  14. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br. J. Cancer. 1999;79(9-10):1487-1493.

    Article  CAS  Google Scholar 

  15. Saakyan SV, Tsygankov АY, Moiseeva NI, Karamysheva АF, Zhil’tsova MG, Tadevosyan SS. Retinoblastoma cell culturing and evaluation of their drug resistance. Bull. Exp. Biol. Med. 2018;165(1):148-153.

    Article  CAS  Google Scholar 

  16. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, Pouillart P, Schlienger P, Servois V, Asselain B. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur. J. Surg. Oncol. 1998;24(2):127-130.

    Article  CAS  Google Scholar 

  17. Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, Foerster MH, Thiel E, Keilholz U. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann. Oncol. 2006;17(12):1826-1829.

    Article  CAS  Google Scholar 

  18. Shields CL, Kaliki S, Livesey M, Walker B, Garoon R, Bucci M, Feinstein E, Pesch A, Gonzalez C, Lally SE, Mashayekhi A, Shields JA. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013;131(8):993-1003.

    Article  Google Scholar 

  19. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881-1885.

    Article  Google Scholar 

  20. Terheyden P, Bröcker EB, Becker JC. Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J. Cancer Res. Clin. Oncol. 2004;130(7):395-399.

    Article  CAS  Google Scholar 

  21. Vertuani S, Dubrovska E, Levitsky V, Jager MJ, Kiessling R, Levitskaya J. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol. Immunother. 2007;56(2):193-204.

    Article  CAS  Google Scholar 

  22. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E; EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12):2309-2315.

    Article  Google Scholar 

  23. Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol. Oncol. Clin. North Am. 2012;26(6):1169-1184.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to А. Yu. Tsygankov.

Additional information

Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 3, pp. 185-190, September, 2020

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saakyan, S.V., Tsygankov, А.Y., Moiseeva, N.I. et al. Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo. Bull Exp Biol Med 170, 142–147 (2020). https://doi.org/10.1007/s10517-020-05020-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-020-05020-3

Key Words

Navigation